Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels

BACKGROUND: Dolutegravir (DTG) is a preferred regimen for all people with HIV including pregnant women, but its effects on the fetus are not fully understood. Periconceptional exposure to DTG has been associated with increased rates of neural tube defects (NTDs), although it is unknown whether this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Haneesha, Lenis, Monica Guzman, Laurette, Evelyn Y., Tejada, Oscar, Sanghvi, Tanvi, Leung, Kit-Yi, Cahill, Lindsay S., Sled, John G., Delgado-Olguín, Paul, Greene, Nicholas D.E., Copp, Andrew J., Serghides, Lena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753150/
https://www.ncbi.nlm.nih.gov/pubmed/33341441
http://dx.doi.org/10.1016/j.ebiom.2020.103167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753150/
https://www.ncbi.nlm.nih.gov/pubmed/33341441
http://dx.doi.org/10.1016/j.ebiom.2020.103167

Ejemplares similares